Review: taking Venlafaxine hydrochloride and Cyclobenzaprine hydrochloride together


Summary

Drug interactions are reported among people who take Venlafaxine hydrochloride and Cyclobenzaprine hydrochloride together. This review analyzes the effectiveness and drug interactions between Venlafaxine hydrochloride and Cyclobenzaprine hydrochloride. It is created by eHealthMe based on reports of 2,249 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Venlafaxine Hydrochloride

Venlafaxine hydrochloride has active ingredients of venlafaxine hydrochloride. It is often used in depression. (latest outcomes from Venlafaxine hydrochloride 5,422 users)

Cyclobenzaprine Hydrochloride

Cyclobenzaprine hydrochloride has active ingredients of cyclobenzaprine hydrochloride. It is often used in muscle spasms. (latest outcomes from Cyclobenzaprine hydrochloride 3,124 users)

On Sep, 17, 2016

2,249 people who take Venlafaxine Hydrochloride, Cyclobenzaprine Hydrochloride are studied.


Number of reports submitted per year:

Venlafaxine hydrochloride and Cyclobenzaprine hydrochloride drug interactions.

Drug effectiveness over time:

Venlafaxine Hydrochloride:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 36.0% - (4 of 11 people)
  • 6 - 12 months: 28.0% - (2 of 7 people)
  • 1 - 2 years: 20.0% - (2 of 10 people)
  • 2 - 5 years: 37.0% - (6 of 16 people)
  • 5 - 10 years: 50.0% - (10 of 20 people)
  • 10+ years: 100.0% - (7 of 7 people)
  • not specified: 100.0% - (1 of 1 people)
Cyclobenzaprine Hydrochloride:
  • < 1 month: 7.0% - (1 of 14 people)
  • 1 - 6 months: 33.0% - (4 of 12 people)
  • 6 - 12 months: 0.0% - (0 of 7 people)
  • 1 - 2 years: 40.0% - (4 of 10 people)
  • 2 - 5 years: 33.0% - (5 of 15 people)
  • 5 - 10 years: 25.0% - (1 of 4 people)
  • 10+ years: 60.0% - (3 of 5 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Venlafaxine Hydrochloride:
  • female: 45.0% - (28 of 62 people)
  • male: 36.0% - (4 of 11 people)
Cyclobenzaprine Hydrochloride:
  • female: 27.0% - (16 of 58 people)
  • male: 22.0% - (2 of 9 people)

Drug effectiveness by age:

Venlafaxine Hydrochloride:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 7 people)
  • 30-39: 50.0% - (8 of 16 people)
  • 40-49: 62.0% - (17 of 27 people)
  • 50-59: 27.0% - (5 of 18 people)
  • 60+: 40.0% - (2 of 5 people)
Cyclobenzaprine Hydrochloride:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 22.0% - (2 of 9 people)
  • 30-39: 36.0% - (4 of 11 people)
  • 40-49: 18.0% - (5 of 27 people)
  • 50-59: 33.0% - (5 of 15 people)
  • 60+: 40.0% - (2 of 5 people)

Most common drug interactions over time *:

< 1 month:
  • acute myocardial infarction
  • headache
  • completed suicide
  • anxiety
  • insomnia
  • malaise
  • confusional state
  • nausea
  • abnormal behaviour
  • delirium
1 - 6 months:
  • gastrooesophageal reflux disease
  • atrial septal defect
  • ventricular septal defect
  • bronchomalacia
  • cardiac failure congestive
  • cardiomegaly
  • coarctation of the aorta
  • laryngomalacia
  • pectus carinatum
  • pulmonary oedema
6 - 12 months:
  • anxiety
  • depression
  • arthropathy
  • cerebral cyst
  • oral herpes
  • osteonecrosis
  • road traffic accident
  • temporomandibular joint syndrome
  • vertigo
  • wound
1 - 2 years:
  • anxiety
  • depression
  • atrial septal defect
  • congenital anomaly
  • maternal exposure during pregnancy
  • arthropathy
  • cerebral cyst
  • oral herpes
  • osteonecrosis
  • temporomandibular joint syndrome
2 - 5 years:
  • anxiety
  • depression
  • suicidal ideation
  • aggression
  • insomnia
  • hot flush
  • nausea
  • panic attack
  • drug withdrawal syndrome
  • homicidal ideation
5 - 10 years:
  • anxiety
  • nausea
  • emotional distress
  • pain
  • constipation
  • cyanosis
  • drug hypersensitivity
  • peripheral ischaemia
  • abdominal discomfort
  • arterial thrombosis
10+ years:
  • memory impairment
  • abdominal discomfort
  • abnormal behaviour
  • accident
  • anxiety
  • aphagia
  • back injury
  • bursa injury
  • chest pain
  • chronic fatigue syndrome
not specified:
  • pain
  • anxiety
  • back pain
  • fatigue
  • depression
  • fall
  • dyspnoea
  • nausea
  • headache
  • arthralgia

Most common drug interactions by gender *:

female:
  • pain
  • anxiety
  • fatigue
  • nausea
  • depression
  • fall
  • headache
  • back pain
  • dyspnoea
  • arthralgia
male:
  • back pain
  • pain
  • depression
  • anxiety
  • constipation
  • dyspnoea
  • fall
  • insomnia
  • pyrexia
  • arthralgia

Most common drug interactions by age *:

0-1:
  • diabetes mellitus
  • gastritis
  • pancreatitis
10-19:
  • anxiety
  • depression
  • pain
  • nausea
  • cough
  • drug ineffective
  • pyrexia
  • drug dependence
  • drug withdrawal syndrome
  • abdominal pain upper
20-29:
  • nausea
  • anxiety
  • back pain
  • cholelithiasis
  • sinus tachycardia
  • depression
  • headache
  • pyrexia
  • suicidal ideation
  • gastrooesophageal reflux disease
30-39:
  • back pain
  • pulmonary embolism
  • anxiety
  • pain in extremity
  • arthralgia
  • diabetes mellitus
  • depression
  • oedema peripheral
  • dyspnoea
  • pain
40-49:
  • pain
  • anxiety
  • depression
  • nausea
  • chest pain
  • headache
  • dyspnoea
  • back pain
  • pain in extremity
  • insomnia
50-59:
  • pain
  • anxiety
  • fatigue
  • headache
  • back pain
  • depression
  • fall
  • nausea
  • arthralgia
  • dyspnoea
60+:
  • fatigue
  • fall
  • back pain
  • pain
  • anxiety
  • dyspnoea
  • headache
  • arthralgia
  • osteonecrosis of jaw
  • anaemia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Venlafaxine hydrochloride and Cyclobenzaprine hydrochloride?

Can you answer these questions?

More questions for: Venlafaxine hydrochloride, Cyclobenzaprine hydrochloride

You may be interested in these reviews

More reviews for: Venlafaxine hydrochloride, Cyclobenzaprine hydrochloride

On eHealthMe, Venlafaxine hydrochloride (venlafaxine hydrochloride) is often used to treat depression. Cyclobenzaprine hydrochloride (cyclobenzaprine hydrochloride) is often used to treat muscle spasms. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.